FOLFOXIRI With or Without Intensification for Rectal Cancer
Phase 2
Recruiting
- Conditions
- Rectal Cancer
- Interventions
- Drug: Control armDrug: Experimental arm
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- CCTU
- Target Recruit Count
- 72
- Registration Number
- NCT03997435
- Locations
- ππ°
The Chinese University of Hong Kong, Hong Kong, Hong Kong
ππ°Department of Oncology, Princess Margaret Hospital, Hong Kong, Hong Kong
ππ°Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Hong Kong
SRAM Study_Postate Cancer
Phase 2
Active, not recruiting
- Conditions
- Advanced Prostate Cancer
- Interventions
- Radiation: Conventional IMRTDrug: SBRT
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- CCTU
- Target Recruit Count
- 120
- Registration Number
- NCT03938649
- Locations
- ππ°
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
Pembrolizumab in Hepatocellular Carcinoma
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- CCTU
- Target Recruit Count
- 30
- Registration Number
- NCT03419481
- Locations
- ππ°
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients
Phase 3
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2017-03-14
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- CCTU
- Target Recruit Count
- 120
- Registration Number
- NCT03079219
- Locations
- ππ°
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
Β© Copyright 2025. All Rights Reserved by MedPath